Abstract
The review of the 2016–2017 marine pharmacology literature was prepared in a manner similar as the 10 prior reviews of this series. Preclinical marine pharmacology research during 2016–2017 assessed 313 marine compounds with novel pharmacology reported by a growing number of investigators from 54 countries. The peer-reviewed literature reported antibacterial, antifungal, antiprotozoal, antituberculosis, and antiviral activities for 123 marine natural products, 111 marine compounds with antidiabetic and anti-inflammatory activities as well as affecting the immune and nervous system, while in contrast 79 marine compounds displayed miscellaneous mechanisms of action which upon further investigation may contribute to several pharmacological classes. Therefore, in 2016–2017, the preclinical marine natural product pharmacology pipeline generated both novel pharmacology as well as potentially new lead compounds for the growing clinical marine pharmaceutical pipeline, and thus sustained with its contributions the global research for novel and effective therapeutic strategies for multiple disease categories.
Highlights
The present review aims to consolidate the 2016–2017 preclinical marine pharmacology literature, with a format similar to our previous 10 reviews of this series which cover the period 1998–2015 [1,2,3,4,5,6,7,8,9,10]
An additional 15 marine natural products (106, 110–123), listed in Table 1 and shown in Figure 1, demonstrated antiviral activity, but the mechanism of action of these compounds remained undetermined at the time of publication: A new aromatic terpenoid (110) isolated form the Japanese marine crinoid Alloeocomatella polycladia which showed moderate activity against the hepatitis C virus (HCV) NS3 helicase [109]; a known sesterterpenoid alotaketal C (111) isolated from the Canadian marine sponge Phorbas sp. shown to activate latent human immunodeficiency virus type-1 (HIV-1) provirus expression [110]; a new cyclic pentapeptide aspergillipeptide D (112) isolated from the South China Sea gorgonian Melitodes squamata-derived fungus Aspergillus sp
This marine pharmacology 2016–2017 review is the eleventh contribution to the marine preclinical pharmacology pipeline review series that was initiated by Alejandro M
Summary
The present review aims to consolidate the 2016–2017 preclinical marine pharmacology literature, with a format similar to our previous 10 reviews of this series which cover the period 1998–2015 [1,2,3,4,5,6,7,8,9,10]. B. subtilis inhibition MR S. aureus inhibition M. luteus and C. urealyticum inhibition.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
